<DOC>
	<DOCNO>NCT00874042</DOCNO>
	<brief_summary>This open-label , dose-escalation/de-escalation study ARQ 197 administer orally combination gemcitabine . The study design determine safety , tolerability maximum tolerate dose ( MTD ) recommend Phase 2 dose ( RP2D ) ARQ 197 administer combination gemcitabine patient advance solid tumor .</brief_summary>
	<brief_title>Dose Escalation Study ARQ 197 Combination With Gemcitabine Adult Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>Enrollment initial cohort 3 6 patient follow traditional `` 3 + 3 '' dose escalation scheme . These patient treat ARQ 197 gemcitabine . ARQ 197 administer mouth BID continuously . Gemcitabine administer intravenous infusion 30 minute weekly 3 consecutive week follow week rest . The dosing schedule ARQ 197 gemcitabine describe . ARQ 197 administer per follow cohort , start week 1 treatment . Cohort -- -- -- ARQ 197 ( mg BID ) 0 -- -- -- -- -- -120 , continuously 1 -- -- -- -- -- -240 , continuously A -- -- -- -- -- -120 ( repeat treatment 2 week follow 1 week pause ) B -- -- -- -- -- -240 ( repeat treatment 2 week follow 1 week pause ) C -- -- -- -- -- -360 ( repeat treatment 2 week follow 1 week pause ) D -- -- -- -- -- -360 ( repeat treatment 3 week follow 1 week pause ) E -- -- -- -- -- -360 , continuously In case DLT , intermediate dosing cohort explore , administer ARQ 197 5 day instead 7 week ARQ 197 administration . For cohort 0 1 , gemcitabine administer dose 1000mg/sqm week 1 treatment , 4 week row first month , 3 consecutive week follow week pause . For cohort , gemcitabine administer start week 2 treatment dose 1000mg/sqm , 3 consecutive week follow week pause . Additional treatment cohort may enrol explore intermediate , high low dos ARQ 197 , indicate tolerability , safety profile , pharmacokinetic ( PK ) profile . Once safe recommend dose level determine , Expanded Cohort 60 patient non-resectable cholangiocarcinoma ( 10 patient ) , breast carcinoma ( 10 patient ) , ovarian carcinoma ( 10 patient ) , endometrial carcinoma carcinoma cervix ( 10 patient total , least five endometrial carcinoma ) . Each group 10 patient may enroll three patient receive least 5-week gemcitabine treatment . The cohort also include 20 patient pancreatic carcinoma ( five 20 patient may receive least 5-week gemcitabine treatment ) .</detailed_description>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Written inform consent grant prior initiation studyspecific screening procedure , give understanding patient right withdraw study time , without prejudice 18 year age old Histologically cytologically confirm locally advance , inoperable metastatic primary solid tumor Measurable disease define Response Evaluation Criteria Solid Tumors ( RECIST ) version 1.1 Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) ≤1 Aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤ 2.5 x upper limit normal ( ULN ) ≤ 5 x ULN metastatic liver disease Hemoglobin ≥ 10 g/dl ( ≥ 9 g/dl expand cohort ) Total bilirubin ≤ 1.5 x ULN Serum creatinine ≤ 1.5 x ULN Absolute neutrophil count ( ANC ) ≥ 1.5 x 10^9/L Platelets ≥ 100 x 10^9/L Women childbearing potential must negative pregnancy test perform within seven day prior start study drug Male female subject childbearing potential must agree use doublebarrier contraceptive measure , oral contraception , avoidance intercourse study 90 day last investigational drug dose receive Other cancer within last three year , exception adequately treat conebiopsied situ carcinoma cervix uteri basal squamous cell carcinoma skin Previous anticancer chemotherapy , radiotherapy , major surgery , immunotherapy investigational agent within 4 week prior first day study define treatment History cardiac disease : congestive heart failure define Class II IV per New York Heart Association ( NYHA ) classification ; active coronary artery disease ( CAD ) ; previously diagnose bradycardia cardiac arrhythmia define ≥ Grade 2 accord National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) ( version 3.0 ) , uncontrolled hypertension ; myocardial infarction occur within 6 month prior study entry ( myocardial infarction occur &gt; 6 month prior study entry permit ) Active clinically serious infection define ≥ Grade 2 accord NCI CTCAE , version 3.0 Substance abuse , medical , psychological social condition may , opinion Investigator , interfere patient 's participation study evaluation study result Any condition unstable could jeopardize safety patient his/her protocol compliance Known human immunodeficiency virus ( HIV ) infection Pregnancy breastfeed Inability swallow oral medication Significant gastrointestinal disorder , opinion Investigator , could interfere absorption ARQ 197 and/or gemcitabine ( e.g . significant , uncontrolled inflammatory bowel disease extensive small bowel resection ) Central nervous system metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>dose escalation</keyword>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>tumor</keyword>
	<keyword>PK</keyword>
</DOC>